Tuberculosis control in those receiving genetically engineering biologic drugs in Chelyabinsk Region
Objective: to summarize the experience in screening and monitoring of tuberculosis infection in individuals receiving genetically engineering biological drugs in Chelyabinsk Region for the period from 2014 to 2018.Subjects and methods. 372 patients were enrolled in the trial, women made 206 (55.4%),...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
New Terra Publishing House
2019-09-01
|
| Series: | Туберкулез и болезни лёгких |
| Subjects: | |
| Online Access: | https://www.tibl-journal.com/jour/article/view/1319 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849771254622453760 |
|---|---|
| author | V. V. Tinkova M. V. Lekhlyayder L. E. Grunina K. V. Savelieva |
| author_facet | V. V. Tinkova M. V. Lekhlyayder L. E. Grunina K. V. Savelieva |
| author_sort | V. V. Tinkova |
| collection | DOAJ |
| description | Objective: to summarize the experience in screening and monitoring of tuberculosis infection in individuals receiving genetically engineering biological drugs in Chelyabinsk Region for the period from 2014 to 2018.Subjects and methods. 372 patients were enrolled in the trial, women made 206 (55.4%), men – 166 (44.6%). The average age of patients was 43.85 ± 1.4 years with no differences by gender. Records of 372 patient's histories were analyzed, they contained information on 1,192 visits of patients referred for screening and monitoring of tuberculosis infection while being treated by genetically engineering biologic drugs.Results. The stages of implementation and the results of screening and monitoring for tuberculosis infection in those receiving therapy with genetically engineering biologic drugs were analyzed at the regional level for 2014-2018. A procedure was developed and introduced to be implemented by a physician for phthisiologic follow-up of patients receiving genetically engineering biologic drugs; indications for computed tomography, IGRA tests were determined, indications for preventive treatment were summarized.Conclusions. The experience presented in the organization of tuberculosis control those treated with genetic engineering immunobiological therapy allows disseminating a similar model to any region. To work with this “new risk group”, i.e. individuals receiving genetically engineering biologic drugs, it is advisable to concentrate such patients in a head tuberculosis control institution to generate statistical data, as well as to ensure the best results for the detection, diagnosis and treatment of tuberculosis in this category of patients. |
| format | Article |
| id | doaj-art-2ab4c8932f6441cb8441e98f924d3ef7 |
| institution | DOAJ |
| issn | 2075-1230 2542-1506 |
| language | Russian |
| publishDate | 2019-09-01 |
| publisher | New Terra Publishing House |
| record_format | Article |
| series | Туберкулез и болезни лёгких |
| spelling | doaj-art-2ab4c8932f6441cb8441e98f924d3ef72025-08-20T03:02:41ZrusNew Terra Publishing HouseТуберкулез и болезни лёгких2075-12302542-15062019-09-0197851310.21292/2075-1230-2019-97-8-5-131319Tuberculosis control in those receiving genetically engineering biologic drugs in Chelyabinsk RegionV. V. Tinkova0M. V. Lekhlyayder1L. E. Grunina2K. V. Savelieva3Chelyabinsk Regional Clinical TB DispensaryChelyabinsk Regional Clinical TB DispensaryChelyabinsk Regional Clinical TB DispensaryChelyabinsk Regional Clinical TB DispensaryObjective: to summarize the experience in screening and monitoring of tuberculosis infection in individuals receiving genetically engineering biological drugs in Chelyabinsk Region for the period from 2014 to 2018.Subjects and methods. 372 patients were enrolled in the trial, women made 206 (55.4%), men – 166 (44.6%). The average age of patients was 43.85 ± 1.4 years with no differences by gender. Records of 372 patient's histories were analyzed, they contained information on 1,192 visits of patients referred for screening and monitoring of tuberculosis infection while being treated by genetically engineering biologic drugs.Results. The stages of implementation and the results of screening and monitoring for tuberculosis infection in those receiving therapy with genetically engineering biologic drugs were analyzed at the regional level for 2014-2018. A procedure was developed and introduced to be implemented by a physician for phthisiologic follow-up of patients receiving genetically engineering biologic drugs; indications for computed tomography, IGRA tests were determined, indications for preventive treatment were summarized.Conclusions. The experience presented in the organization of tuberculosis control those treated with genetic engineering immunobiological therapy allows disseminating a similar model to any region. To work with this “new risk group”, i.e. individuals receiving genetically engineering biologic drugs, it is advisable to concentrate such patients in a head tuberculosis control institution to generate statistical data, as well as to ensure the best results for the detection, diagnosis and treatment of tuberculosis in this category of patients.https://www.tibl-journal.com/jour/article/view/1319genetically engineering biologic drugsscreening and monitoring of tuberculous infectionphthisiologic support |
| spellingShingle | V. V. Tinkova M. V. Lekhlyayder L. E. Grunina K. V. Savelieva Tuberculosis control in those receiving genetically engineering biologic drugs in Chelyabinsk Region Туберкулез и болезни лёгких genetically engineering biologic drugs screening and monitoring of tuberculous infection phthisiologic support |
| title | Tuberculosis control in those receiving genetically engineering biologic drugs in Chelyabinsk Region |
| title_full | Tuberculosis control in those receiving genetically engineering biologic drugs in Chelyabinsk Region |
| title_fullStr | Tuberculosis control in those receiving genetically engineering biologic drugs in Chelyabinsk Region |
| title_full_unstemmed | Tuberculosis control in those receiving genetically engineering biologic drugs in Chelyabinsk Region |
| title_short | Tuberculosis control in those receiving genetically engineering biologic drugs in Chelyabinsk Region |
| title_sort | tuberculosis control in those receiving genetically engineering biologic drugs in chelyabinsk region |
| topic | genetically engineering biologic drugs screening and monitoring of tuberculous infection phthisiologic support |
| url | https://www.tibl-journal.com/jour/article/view/1319 |
| work_keys_str_mv | AT vvtinkova tuberculosiscontrolinthosereceivinggeneticallyengineeringbiologicdrugsinchelyabinskregion AT mvlekhlyayder tuberculosiscontrolinthosereceivinggeneticallyengineeringbiologicdrugsinchelyabinskregion AT legrunina tuberculosiscontrolinthosereceivinggeneticallyengineeringbiologicdrugsinchelyabinskregion AT kvsavelieva tuberculosiscontrolinthosereceivinggeneticallyengineeringbiologicdrugsinchelyabinskregion |